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SLICC/ACR DIAbstract Aim of the work: The aim of this study was to identify the relationship between disease
activity in SLE Egyptian females and the presence, severity and pattern of major depression in these
patients.
Patients and methods: The study sample included 100 female patients; fifty SLE patients and fifty
healthy adults with matching age serving as control. Patients were assessed using Beck Inventory
Score for the presence of major depression, SLEDAI to determine disease activity, SLICC/ACR
damage index and HAQ score for functional disability.
Results: The majority of patients had symptoms of major depression 32/50 (64%) based on Beck
Inventory Score while in controls only 16/50 (36%) had major depression. The most common
depressive symptoms in SLE patients were: Guilty feeling (92%), Self-dislike (91.6%), Self-
criticalness (90.4%), Crying spells (87.5%), Loss of pleasure (83.3%), Change in appetite
(83.3%), Agitation (82.8%) and Pessimism (82%). Patients with major depression presented a trend
toward having greater severity of SLE disease activity compared with those without major depres-
sion (p= 0.04). The presence of major depression was significantly associated with functional dis-
ability measured by HAQ score (p= 0.01). The patients with major depression did not differ
significantly from patients without major depression regarding their steroid dosage (p= 0.55),
SLICC/ACR damage score (p= 0.16) and disease duration (p= 0.69) but differed significantly
as regards Beck Hopelessness Scale (p< 0.0001) and suicidal ideation score (p= 0.009).
Conclusion: Major depression was highly presented in Egyptian SLE patients (64%); its severity
was associated with disease activity, but not with steroid administration, cumulative damage or
disease duration.
 2015 The Authors. Production and hosting by Elsevier B.V. on behalf of Egyptian Society of Rheumatic
Diseases. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/
licenses/by-nc-nd/4.0/).sr City,
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Systemic lupus erythematosus (SLE) is a chronic autoimmune
disease which usually affects multiple organ systems including
the central nervous system (CNS) [1]. SLE is potentially dis-
abling and many challenges are associated with coping with
this chronic disease and the treatment regimen. Thus, SLE
can have severe impact on individual quality of life and pose
serious obstacles to achieving life goals in young individuals
who are mostly affected [2]. Neuropsychiatric SLE (NPSLE)
refers to the various psychiatric and neurologic manifestations
that develop secondary to involvement of the CNS in patients
with SLE [3].
Neuropsychiatric manifestations of SLE have been
reported in Egyptian patients including seizures, mood affec-
tion, cognitive impairment, psychosis, headache, neuropathy
and stroke [4,5]. Cognitive dysfunction is a prominent manifes-
tation in NPSLE. Neuropsychiatric deficits and memory
impairment in SLE patients affect their daily activities [6].
Cognitive dysfunction was also found to be a prominent
feature in asymptomatic SLE Egyptian patients [7] and depres-
sion has been reported in 13.3% in another study [8].
Major depression is one of the most frequent psychiatric
disorders observed in patients with SLE, with point prevalence
rates between 10.8% and 39.6%, which is much higher than in
the general population [9]. Depression in SLE is multifactorial.
Major depression may be linked to neurotransmitter dysfunc-
tion and immune activation (lymphocyte abnormalities and
cytokine expression) [10,11]. A recent study has shown that
high dose prednisone (P20 mg daily) is one important inde-
pendent risk factor and also cutaneous activity and certain
types of neurologic activity (myelitis) are predictive of depres-
sion [12]. Depression in SLE aggravates fatigue, pain and
psychological stress, and reduces drug compliance, leading to
significant further impairment of quality of life and work
disability [13,14]. The severity of depression may also increase
the risk of suicidal thoughts [15,16].
The aim of this work is to evaluate the presence of major
depressive disorders and the contributing factors to it in
Egyptian female patients with systemic lupus erythematosus
and also identify the association between SLE disease activity
and depression severity.
2. Patients and methods
One hundred female participants were enrolled in the present
study. They were all recruited from the Rheumatology and
Rehabilitation both inpatient and outpatient clinics at Kasr
Al-Ainy Hospital, Cairo University. Participants were divided
into 2 groups: in Group (A) the studied sample included fifty
SLE female patients fulfilling the ACR diagnostic criteria
[17]. Only adult females (above 18 years old) without past his-
tory of psychiatric illness or serious medical illness were
selected. Group (B): 50 adults served as control and were
selected from workers at Kasr Al-Ainy matched for age,
education and socioeconomic status. The study was submitted
and approved by the Ethics Committee. Participants gave their
oral and written consents after informing them about the
goals, methods and expected benefits of the study.
Participants’ socio-demographic data were gathered includ-
ing age, educational level, employment and marital status.All Lupus patients underwent history taking, full clinical
examination and laboratory investigations (including erythro-
cyte sedimentation rate, complete blood count, liver and kid-
ney function tests, urine analysis and autoimmune profile
tests). Assessment of disease activity was done using systemic
lupus disease activity index (SLEDAI) scoring system [18]
and patients were classified as inactive, having mild, moderate
or severe activity. Also Assessment of organ damage was car-
ried out using the Systemic Lupus Collaborating Clinics/ACR
damage index (SLICC/ACR DI) [19] and of functional disabil-
ity using the Health Assessment Questionnaire (HAQ) [20].
Psychometric assessment tools: A psychiatrist interviewed
the patients and control three days weekly. He evaluated
depression using the Beck Depression Inventory Score (BDS)
[21]: 21 groups of statements on a 4 point scale. The score
ranges from (0 to 63) where higher scores denote greater sever-
ity of depression. He also used the Beck Hopelessness Scale
(BHS) [22] to assess hopelessness using a questionnaire that
consists of twenty true or false questions. This scale ranges
from (0 to 20), where mild cases range from (4 to 8), moderate
cases (9 to 14) and severe cases (15 to 20).The intensity of sui-
cidal thoughts during the preceding week was assessed by the
Beck Suicidal Ideation Scale (BSI) [23]. This is a 19 item
self-report questionnaire. Each question scores (0 to 2) and
the score ranges from (0 to 38) with higher scores indicating
more intense suicidal ideation.
Statistical analysis: Descriptive analysis of the results was
done using (minimum, maximum, median, mean and standard
deviation). Comparison between the study groups was per-
formed using Chi square test. The Fisher Exact test was used
instead when the expected frequency was less than 5. Correla-
tion between different variables was carried out using the
Spearman correlation equation. All statistical analysis was per-
formed using SPSS 15.0 (Statistical package for the Social
Science, USA). Statistical significance was defined as a p
value < 0.05.3. Results
Fifty SLE patients were included in our study, their age ranged
from 19 to 45 years old with a mean of 27.9 ± 6.28 and their
disease duration ranged from 0.41 to 19 years with a mean of
5.5 ± 4.5 years. Details of the socio-demographic features of
the SLE patients are shown in Table 1. The clinical manifesta-
tions, immune profile and disease activity are presented in
Table 2. 22% of the patients had mild to moderate activity
on the SLE disease activity index while 24% had severe
activity. According to the SLICC/ACR DI, hand deformity
and DVT were present in 4%, osteoporosis & avascular
necrosis, peripheral neuropathy, epilepsy and end stage renal
disease in 2%.
Thirty-two (64%) SLE patients had major depression (MD)
according to the Beck Depression Score. On the other hand,
sixteen (36%) of the control suffered from major depression.
Based on the Beck Hopelessness Scale; 34%, 14% and 22%
of the patients were found to have mild, moderate and severe
levels of hopelessness respectively and 20% of the patients
showed symptoms of suicidal probability (Table 3). There
was no significant difference in the socio-demographic features
between the SLE patients with and without major depression.
The BHS ranged from 0 to 18 with a median of 10 in MD
Table 1 Socio-demographic features of the female systemic
lupus erythematosus (SLE) patients.






Not educated 8 (16)
Primary school 12 (24)









SLE: systemic lupus erythematosus.
Table 2 Clinical manifestations, laboratory features and




Clinical manifestations Fever 10 (20)
Fatigue 26 (52)
Weight loss 10 (20)
Malar rash 36 (72)
Photosensitivity 29 (58)





Deep venous thrombosis 5 (10)




Immune profile ANA positivity 50 (100)
DNA positivity 43 (86)
APL positivity 11 (22)
Anti Ro/La positivity 5 (10)
C3 and C4 consumption 23 (46)
SLEDAI Inactive < 2 27 (54)
Mild to moderate (2–20) 11 (22)
Severe > 20 12 (24)
SLE: systemic lupus erythematosus, SLEDAI: SLE disease activity
index.
Table 3 Beck scores of psychological parameters of systemic
lupus erythematosus (SLE) patients.
Beck scores n (%) SLE patients (n= 50)
Depression
No Major depression 18 (36)
Major depression 32 (64)
Hopelessness Scale
No symptoms (0–4) 15 (30)
Mild (>4–8) 17 (34)
Moderate (>8–14) 7 (14)
Severe (>14–20) 11 (22)
Suicidal Ideation Scale
No symptoms of suicide probability 40 (80)
Symptoms of suicide probability 10 (20)
SLE: systemic lupus erythematosus.
Table 4 Comparison between systemic lupus erythematosus
(SLE) patients with and without major depression as regards
different disease parameters.
Parameter MD NMD p
Median (range) (n= 32) (n= 18)
Disease duration (y) 4 (0.5–17) 5 (0.5–19) 0.69
Steroid dosage (mg/d) 20 (5–1000) 20 (5–60) 0.55
SLEDAI 15 (0–29) 8 (0–13) 0.04
SLICC/ACR DI 0 (0–3) 0 (0–3) 0.16
HAQ score 0.3 (0–1.5) 0 (0–1.2) 0.01
MD: major depression, NMD: no major depression, SLEDAI: SLE
disease activity index, SLICC/ACR DI: systemic lupus interna-
tional collaborating clinics/American College of Rheumatology
Damage Index, HAQ: Health Assessment Questionnaire. Bold
values are significant at p< 0.05.
Disease activity among systemic lupus erythematosus females S3patients and the BSI ranged from 0 to 17 while in those with-
out MD, the BHS ranged from 0 to 7 and none of them had
suicidal ideation. Patients with MD had significantly higherBHS (p< 0.0001) and BSI (p= 0.009) than those patients
with no major depression (NMD). On comparing different dis-
ease parameters between those with MD and those with NMD,
the SLEDAI (p= 0.04) and HAQ (p= 0.01) were signifi-
cantly higher in those with MD than in those without.
However, no significant difference was found as regards the
disease duration, steroid dosage and SLICC/ACR DI
(Table 4).
The most common depressive symptoms among SLE
patients were: Guilty feeling (92%), Self-dislike (91.6%),
Self-criticalness (90.4%), Crying spells (87.5%), Loss of plea-
sure (83.3%), Change in appetite (83.3%), Agitation
(82.8%), Pessimism (82%), Tiredness or fatigue (72.9%), Loss
of energy (72.5%) and Sadness (72%). However the most
common symptoms of depression in the control group were
sadness (30%), loss of energy (28%) and tiredness (24%)
(Fig. 1). The severity of some of the symptoms in the Beck
Depression Score is represented in Table 5. These symptoms
were significantly higher in the SLE patients compared to the
control group. Other symptoms including sense of failure,
social withdrawal, sleep disturbances, weight loss, etc. showed
no significant difference when compared between the two
groups.
Figure 1 Comparison between patterns of depression among systemic lupus erythematosus (SLE) patients and control group.
Table 5 Comparison between systemic lupus erythematosus











Sadness No 0 (0) 5 (31.3) <0.001











Mild 6 (18.8) 4 (25)
Moderate 3 (9.4) 0 (0)
Severe 9 (28) 0 (0)
Very severe 3 (9.4) 0 (0)
Loss of pleasure No 2 (6.3) 10
(62.5)
<0.05




Severe 8 (25) 2 (12.5)
Very severe 5 (15.6) 0 (0)









Severe 0 (0) 0 (0)





Mild 7 (21.9) 2 (12.5)
Moderate 4 (12.4) 0 (0)
Severe 4 (12.4) 0 (0)
Very severe 7 (21.9) 0 (0)
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The majority of patients had symptoms of major depression
32/50 (64%) based on Beck Inventory Score while in control
group only 16/50 (36%) had major depression. The percentage
of patients suffering from depression measured by BDS scores
in our sample was 64%, which was higher than the prevalence
described by other studies conducted among SLE patients
16% [24], 23.34% [25], 30% [26], 40.5% [27], 39– 46% [28],
49% [29] and 60% in a recent study [15].
The difference observed may be due to various methodolo-
gies, patient samples, studies were conducted among women
only, sample sizes, and different cultural and social
backgrounds [28]. On measuring the activity of the disease
by SLEDAI score, it was found that 46% (23/50) of SLE
patients had active disease, 65% with MD and 35% without
major depression. It was found that the severity of depression
was associated with disease activity, but not with steroid
administration, age or disease duration. This was consistent
with the study done by Zakeri and colleagues [15], where in
total, 60% of patients achieved scores indicating depression.
These results were consistent with the studies conducted by
others [27,29,30]. Patients with MD showed significant
higher mean BHS (p< 0.0001) and BSI (p= 0.009) compared
to NMD. This was consistent with many studies done
[15,16,24–27]. According to Beck’s assumption, hopelessness
appeared to be a mediator between depressive symptoms and
the wish to kill oneself. These findings are relevant for preven-
tion and therapy. They suggest that targeting hopelessness may
be as important in adolescents as in adults to reduce suicidal
ideation and prevent suicidal attempts.
SLE is potentially disabling [28] and depression can aggra-
vate disability, absence from work, in addition to reducing
drug compliance, increasing utilization of health care services
and the risk of suicide [29–38]. This is in line with our study
where SLE patients with MD reported more disability
(measured by HAQ) compared with those without MD
(p= 0.01). On the other hand patients with MD showed
no significant difference from NMD patients as regards











Self criticalness No 13 (40) 14
(87.5)
0.001
Mild 5 (15.6) 1 (6.3)
Moderate 5 (15.6) 0 (0)
Severe 8 (25) 1 (6.3)
Very severe 1 (3.1) 0 (0)
Crying spells No 4 (12.5) 12 (75) <0.05
Mild 7 (21.9) 1 (6.3)




Very severe 3 (9.4) 1 (6.3)
Agitation No (n= 15) 3 (9.4) 9 (56.3) 0.001
Mild (n= 7) 4 (12.5) 3 (18.8)
Moderate
(n= 7)






Loss of energy No 3 (9.4) 6 (37.5) 0.002







Very severe 2 (6.3) 0 (0)
Tiredness &
fatigue
No 5 (15.6) 7 (43.8) 0.04
Mild 3 (9.4) 3 (18.8)




Very severe 7 (21.9) 0 (0)
Change in
appetite






Moderate 6 (18.8) 3 (18.8)
Severe 8 (25) 0 (0)
BDS: Beck Depression Score. Bold values are significant at
p< 0.05.
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age caused by the disease itself.
In the current study the most frequently reported symptoms
were guilty feeling, self-dislike, self-criticalness and spells of
crying which are closely related to depression. This is different
from the study carried by Zakeri et al. [15] in which weakness
and fatigue (87.2%), irritability (80.8%), and sadness (75.6%)
were the most prevalent symptoms. Well this could be
explained by the fact that that weakness and fatigue are
somatic symptoms that may accompany SLE and may not
be related to the mental state of the patient.
Twenty percent of the SLE patients in our sample showed a
high score of suicidal ideation. This frequency is greater than
that reported in Hong Kong (12%) [31] the Middle East(10.5%) [15], Chile (9.6%) [38] and Japan (8.4%) [39] and
could be related to the higher disease activity of our SLE
patients (25% of patients had SLEDAI scoresP 20). It is
documented that SLE patients with active disease are more
likely to be depressed [40]. Moreover, the socio-economic
status and educational level of our patients was lower than
those in the previously mentioned studies which might be
another contributing factor to the higher prevalence of
suicidal ideation in our study.
In conclusion, depression is highly presented among SLE
Egyptian patients. The severity of depression is associated with
disease activity and patients with major depression report
more disability. Hence, psychiatric assessment of SLE patients
should be considered as part of their clinical evaluation. Early
detection and intervention in management of depression could
have dramatic impact in controlling disease activity and the
patients’ quality of life. Patients should be informed of avail-
able support groups and referred to psychiatric rehabilitation
centers whenever indicated.Conflict of interest
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